Editas Medicine (NASDAQ:EDIT) and Azzur Group have extended their contract to develop and manufacture cell therapies in pre-clinical and early stages. The contract involves using Azzur’s Cleanrooms on Demand site in Devens, Mass., for Editas’ candidates, including EDIT-301 for sickle cell disease and beta thalassemia.
- Editas Medicine (NASDAQ:EDIT) and Azzur Group have expanded a contract for the development and manufacture of cell therapies in pre-clinical and early stages.
- Editas (EDIT) has been using Azzur’s Cleanrooms on Demand site in Devens, Mass., since 2020 for the development of several candidates, including EDIT-301 for sickle cell disease and beta thalassemia.
- The expanded contract includes compliant cleanroom space and lab services.
Source: SeekingAlpha